Cargando…
High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells
Approximately 25–40% of patients with lung cancer show bone metastasis. Bone modifying agents reduce skeletal-related events (SREs), but they do not significantly improve overall survival. Therefore, novel therapeutic approaches are urgently required. In this study, we investigated the anti-tumor ef...
Autores principales: | Fujita, Hidenori, Gomori, Akira, Fujioka, Yayoi, Kataoka, Yuki, Tanaka, Kenji, Hashimoto, Akihiro, Suzuki, Takamasa, Ito, Kenjiro, Haruma, Tomonori, Yamamoto-Yokoi, Hiromi, Harada, Naomoto, Sakuragi, Motomu, Oda, Nobuyuki, Matsuo, Kenichi, Inada, Masaki, Yonekura, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063576/ https://www.ncbi.nlm.nih.gov/pubmed/27736957 http://dx.doi.org/10.1371/journal.pone.0164830 |
Ejemplares similares
-
Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy
por: Shibutani, Toshihiro, et al.
Publicado: (2023) -
Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019) -
Giant cell tumor of bone: A single center study of 115 cases
por: Deventer, Niklas, et al.
Publicado: (2022) -
Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma
por: Yamada, Shutaro, et al.
Publicado: (2017) -
TAS‐115 inhibits PDGFRα/AXL/FLT‐3 signaling and suppresses lung metastasis of osteosarcoma
por: Yasuda, Naohiro, et al.
Publicado: (2020)